(Funded by the U.S. Department of Defense and the National Institutes of Health)
Scientists from the City University of New York, the Memorial Sloan Kettering Cancer Center, and Weill Cornell Medicine have developed a groundbreaking approach using nanoparticles that are primarily composed of a drug and a thin peptide coating which improves solubility, enhances stability in the body, and optimizes delivery to targeted areas. In leukemia models, the nanoparticles were more effective at shrinking tumors compared to the drug alone. “Using specially designed peptides, we can build nanomedicines that make existing drugs more effective and less toxic and even enable the development of drugs that might not be able to work without these nanoparticles,” said Daniel Heller, one of the scientists involved in this study.

(Funded by the National Institutes of Health)
A new experimental vaccine developed by researchers from the Massachusetts Institute of Technology, Massachusetts General Hospital, Caltech, and the University of Cambridge in the United Kingdom could offer protection against emerging variants of SARS-CoV-2, as well as related coronaviruses, known as sarbecoviruses, that could spill over from animals to humans. Sarbecoviruses include SARS-CoV-2 (the virus that causes COVID-19) and the virus that led to the outbreak of the original SARS in the early 2000s. By attaching up to eight different versions of sarbecovirus receptor-binding proteins to nanoparticles, the researchers created a vaccine that generates antibodies that recognize regions of receptor-binding proteins that tend to remain unchanged across all strains of the viruses.

(Funded by the U.S. National Science Foundation, the U.S. Department of Defense, and the National Institutes of Health)
Researchers from Northwestern University, Duke University, and Cornell University have developed the first two-dimensional mechanically interlocked material. Looking like the interlocking links in chainmail, the nanoscale material exhibits exceptional flexibility and strength. With further work, this material holds promise for use in high-performance, light-weight body armor and other uses that demand lightweight, flexible, and tough materials. “We made a completely new polymer structure,” said William Dichtel, the study’s corresponding author. “It’s similar to chainmail in that it cannot easily rip because each of the mechanical bonds has a bit of freedom to slide around. If you pull it, it can dissipate the applied force in multiple directions. And if you want to rip it apart, you would have to break it in many, many different places.”

(Funded by the National Institutes of Health)
Researchers from The Johns Hopkins University School of Medicine, the Van Andel Institute in Grand Rapids, MI, and the Chinese Academy of Sciences have discovered that a mouse protein, called STELLA, disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells. First, the researchers found the part of the protein, or peptide, that was required to activate tumor suppressor genes in human colorectal cancer cells. Then, they designed a lipid nanoparticle – an ultratiny drug delivery vehicle made of fatty molecules – to deliver the messenger RNA (mRNA) that codes for this peptide to cells. The therapy performed well in mice, activating tumor suppressor genes and impairing tumor growth. Next, the researchers plan to test this therapy on human patients through clinical trials.

(Funded by the National Institutes of Health)
Researchers from the University of Pennsylvania; the Wistar Institute in Philadelphia, PA; Central South University in Changsha, China, have engineered small nano-sized capsules called extracellular vesicles from human cells to target a cell-surface receptor called DR5 (death receptor 5) that many tumor cells have. When activated, DR5 can trigger the death of these tumor cells by a self-destruct process called apoptosis. Researchers have been trying for more than 20 years to develop successful DR5-targeting cancer treatments. The new approach outperformed DR5-targeting antibodies, which have been considered a leading DR5-targeting strategy. The small extracellular vesicles efficiently killed multiple cancer cell types in lab-dish tests and blocked tumor growth in mouse models, enabling longer survival than DR5-targeting antibodies.